Dacoplice 30mg Tablet
Rx RequiredSalt Composition: Dacomitinib
Expiry Date: 01/2028
Price on Request
Inclusive of all taxes
30 tablets in Bottle
About The Product
Lung Cancer
Description
Dacoplice 30mg Tablet is a Target therapy based anticancer medication prescribed by the doctor to treat advanced Non Small Cell Lung Cancer (NSCLC) with specific EGFR gene mutation. Dacoplice Tablet contains Erlotinib that belongs to the class of tyrosine kinase inhibitor.
Erlitinib blocks the abnormal EGFR protein kinase that is responsible for cancer cell growth and proliferation via angiogenesis.
Common Side Effects
- Dacoplice 30mg Tablet is a chemical based targeted anti cancer medication.
- Like any other chemotherapeutic drug, it also has multiple side effects that range from common to extreme.
- Consult your doctor, if symptoms persists for longer period of time or if you experience any of the serious side effects. ● Vomiting ● Nausea ● Fatigue ● Diarrhea ● Decreased Appetite ● Abdominal Pain ● Dry Skin ● Nail Inflammation ● Mouth Sores ● Constipation ● Rashes ● Weight Loss ● Headache ● Arthralgia ● Dyspnea ● Gastrointestinal Perforation ● Liver Toxicity ● Kidney Issues ● Pneumonitis ● Visionm Related Issues
Dosage And Administration
- Dacoplice 30mg Tablet is generally used for first dose reduction for adverse reactions.This medicine is taken orally as whole on an empty stomach, without breaking, biting or chewing.
- Consult your doctor for exact dosage that is especially meant for you.
Mechanism Of Action
Dacoplice 30mg Tablet contains Dacomitinib that belongs to irreversible pan-HER tyrosine kinase inhibitor class. It covalently binds to Cysteine residues in kinase domains EGFR.
As a result, blocking their activation and downstream signalling pathways like RAS-RAF-MEK-ERK and PI3K-AKT. This stops ligand-induced receptor dimerization, autophosphorylation, and signaling cascades that cause EGFR-mutated NSCLC cells to proliferate uncontrollably.
Safety Advice
Faqs
Dacoplice 30mg Tablet cause harm to growing fetus as well as is taratogenic in nature.
Thus, it is not recommended during pregnancy for treatment.
References
• Shirley, M. (2018).
Dacomitinib: first global approval. Drugs, 78(18), 1947-1953. • Wu, Y.
L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., ... & Mok, T.
S. (2017).
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology, 18(11), 1454-1466. • Cheng, W.
C., Lin, C. C., Liao, W.
C., Lin, Y. C., Chen, C.
H., Chen, H. J., ... & Hsia, T.
C. (2024).
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study. BMC cancer, 24(1), 228. • Reed, J.
E., & Smaill, J. B.
(2016). The discovery of dacomitinib, a potent irreversible EGFR inhibitor.
In Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1 (pp. 207-233).
American Chemical Society.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
.png&w=48&q=75 "Cart"){kind=small}
9655.png&w=48&q=75 "Home"){kind=small}
